证券代码：832471 证券简称：美邦科技 公告编号：2024-080 河北美邦工程科技股份有限公司 回购进展情况公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误 导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带法律 责任。 一、 回购方案基本情况 （一）审议及表决情况 河北美邦工程科技股份有限公司（以下简称"公司"）于 2023 年 11 月 28 日召开 第三届董事会第二十二次会议、第三届监事会第十七次会议，审议通过了《关于回购 股份方案的议案》。根据《公司法》《公司章程》等规定，公司回购本公司股份用于员 工持股计划或者股权激励的情形，经三分之二以上董事出席的董事会会议决议后，无 需再提交股东大会审议。 （二）回购用途及目的 基于对公司未来发展前景的信心和公司价值的认可，为建立、健全公司的长效激 励机制，吸引和留住优秀人才，充分调动管理层及员工的积极性，共同促进公司持续 稳定健康发展，在综合考虑公司发展前景、经营情况、财务状况及未来盈利能力等因 素的基础上，公司拟以自有资金回购公司股份，用于实施股权激励或员工持股计划。 （三） 回购方式 本次回购方式为竞价 ...

本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2024 年 10 月 30 日 证券代码：832471 证券简称：美邦科技 公告编号：2024-077 河北美邦工程科技股份有限公司 第四届董事会第四次会议决议公告 2.会议召开地点：公司会议室 3.会议召开方式：现场及通讯 4.发出董事会会议通知的时间和方式：2024 年 10 月 25 日以邮件方式发出 5.会议主持人：董事长高文杲 6.会议列席人员：监事会成员、董事会秘书及公司高级管理人员 7.召开情况合法、合规、合章程性说明： 本次会议的召开、召集和表决程序符合《公司法》和《公司章程》有关法 律法规以及公司内部治理规则的规定，所作决议合法有效。 （二）会议出席情况 会议应出席董事 7 人，出席和授权出席董事 7 人。 二、议案审议情况 （一）审议通过《关于 2024 年第三季度报告的议案》 1.议案内容： 具体内容详见公司在北京证券交易所信息披露平台(www.bse.cn)上披露 的《 ...

证券代码：832471 证券简称：美邦科技 公告编号：2024-078 （一）会议召开情况 5.会议主持人：监事会主席马记 6.召开情况合法、合规、合章程性说明： 本次会议的召开、召集和表决程序符合《公司法》和《公司章程》有关法 律法规以及公司内部治理规则的规定，所作决议合法有效。 （二）会议出席情况 会议应出席监事 3 人，出席和授权出席监事 3 人。 河北美邦工程科技股份有限公司 第四届监事会第四次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、会议召开和出席情况 2.议案表决结果：同意 3 票；反对 0 票；弃权 0 票。 1.会议召开时间：2024 年 10 月 30 日 2.会议召开地点：公司会议室 3.会议召开方式：现场及通讯 4.发出监事会会议通知的时间和方式：2024 年 10 月 25 日以邮件方式发出 3.回避表决情况 本议案不涉及关联交易事项，无需回避表决。 本议案无需提交股东大会审议。 三、备查文件目录 （一）《河北美邦工程科技股份有限公司第四届监事会第四次会议 ...

Financial Performance - Operating revenue for the first nine months of 2024 was ¥394,229,848.87, representing a year-on-year growth of 15.78%[6] - Net profit attributable to shareholders for the first nine months of 2024 was ¥17,742,635.59, a slight increase of 1.60% from the previous year[6] - The total profit for the first nine months of 2024 was ¥15,511,925.92, compared to ¥18,136,862.27 in the same period of 2023, reflecting a decline of approximately 14.3%[28] - The net profit for the first nine months of 2024 was ¥13,151,274.43, compared to ¥16,153,778.52 in the same period of 2023, indicating a decrease of about 18.5%[28] - The operating profit for the first nine months of 2024 was ¥15,511,678.92, down from ¥18,620,552.70 in the same period of 2023, showing a decrease of about 16.9%[28] - The company recorded other comprehensive income after tax of -¥7,143.72, compared to ¥68,558.96 in the previous period, indicating a significant decline[28] - The total comprehensive income for the first nine months of 2024 was ¥13,144,130.71, down from ¥16,222,337.48 in the same period of 2023, reflecting a decrease of approximately 18.9%[29] Cash Flow - The net cash flow from operating activities improved significantly to ¥19,640,893.64, a 313.29% increase compared to the same period last year[6] - Operating cash flow for the first nine months of 2024 was CNY 19,640,893.64, a significant improvement from a negative cash flow of CNY -9,208,418.10 in the same period of 2023[31] - Total cash inflow from operating activities was CNY 336,084,740.88, slightly down from CNY 342,943,205.83 in the previous year[30] - Cash outflow for operating activities decreased to CNY 316,443,847.24 from CNY 352,151,623.93, showing a reduction of approximately 10.1%[30] - The company reported a net increase in cash and cash equivalents of CNY 10,754,193.58, contrasting with a decrease of CNY -13,846,533.71 in the prior year[31] - The ending balance of cash and cash equivalents as of September 2024 was CNY 99,794,825.13, compared to CNY 137,236,743.80 at the end of September 2023[31] Assets and Liabilities - Total assets as of September 30, 2024, reached ¥1,021,481,107.38, an increase of 7.08% compared to the end of the previous year[6] - The company's debt-to-asset ratio (consolidated) was 33.66%, up from 29.78% at the end of the previous year[6] - The total liabilities amounted to 343,841,839.14 CNY, while total equity reached 677,639,268.24 CNY, indicating a healthy equity position[22] - The company has pledged assets totaling 188,176,575.79 CNY, which represents 18.42% of total assets, to secure bank loans[18] - Current assets decreased slightly to 431,463,027.29 CNY from 437,777,843.53 CNY, indicating a decline of about 1.4%[20] - The company's fixed assets decreased to 251,988,872.90 CNY from 283,336,613.41 CNY, a reduction of approximately 11.0%[20] Shareholder Information - The total number of ordinary shares is 83,200,000, with 34.36% being unrestricted shares and 65.64% being restricted shares[10] - The top ten shareholders collectively hold 66.73% of the shares, with the largest shareholder owning 27.67%[11] - The company plans to repurchase shares at a price not exceeding ¥12.80 per share, with a total repurchase fund between ¥10,000,000 and ¥20,000,000, potentially acquiring 781,250 to 1,562,500 shares[15] - As of the reporting period, the company repurchased 1,231,000 shares, accounting for 1.48% of the total share capital, with a total expenditure of 11,217,892.58 CNY, which is 56.09% of the planned repurchase fund[16] Research and Development - Research and development expenses increased by 32.61% to ¥19,368,170.27, reflecting the company's commitment to new technology and product development[7] - Research and development expenses increased to ¥19,368,170.27 in 2024 from ¥14,605,859.97 in 2023, reflecting a growth of approximately 32.1%[26] - Research and development expenses increased to ¥2,130,290.19 from ¥1,837,040.69, representing a growth of approximately 15.9%[28] Investment Activities - The cash flow from investment activities showed a net outflow of ¥32,296,503.22, an increase of 67.41% due to investments in subsidiaries[8] - Total cash inflow from investment activities decreased to CNY 113,876,542.09 in 2024 from CNY 318,073,543.70 in 2023, indicating a decline of approximately 64.2%[31] - Cash outflow for investment activities was CNY 146,173,045.31, down from CNY 417,170,233.65 in the previous year, representing a reduction of about 65%[31] Other Financial Metrics - The company's financial expenses rose by 88.22% to ¥1,177,507.84, primarily due to increased interest expenses from bank loans[7] - The company reported a credit impairment loss of ¥4,762,830.02, a significant increase from a reversal of ¥2,728,214.77 in the previous year[28] - The company incurred sales expenses of ¥480,581.99, a decrease from ¥779,512.73 in the previous year, indicating a reduction of about 38.4%[28] - The company has no significant litigation or arbitration matters during the reporting period[13] - The company has not engaged in any external loans during the reporting period[13] - The company has not reported any significant related party transactions during the reporting period[13] - The company has not disclosed any major events or issues that would impact its operations negatively[13]

| 日期 | 代码 | 简称 | 成交数量（股） | 成交金额（万元） | 披露原因 | | --- | --- | --- | --- | --- | --- | | 2024-10- | | | | | 异常期间涨跌幅偏离值累计 | | 25 | 872374 | 云里物里 | 10711936.0 | 27300.04 | 达到64.84% | | 2024-10- | 430198 | 微创光电 | 58845916.0 | 79017.62 | 异常期间涨跌幅偏离值累计 | | 25 | | | | | 达到47.70% | | 2024-10- | 839167 | 同享科技 | 45570754.0 | 128413.2 | 异常期间涨跌幅偏离值累计 | | 25 | | | | | 达到42.74% | | 2024-10- 25 | 872374 | 云里物里 | 2384250 | 7965.78 | 当日收盘价涨幅达到30.00% | | 2024-10- 25 | 830779 | 武汉蓝电 | 3552531 | 11909.28 | 当日收盘价涨幅达到30.00% | | 2024 ...

| | 公告日期 2024-10-25 | 异常期间 | 无 | | | | --- | --- | --- | --- | --- | --- | | | 美邦科技(832471) 连续竞价 | 成交数量 | 15932089.0 | 成交金额（万 | 31927.33 | | | | （股） | | 元） | | | | 涉及事项 当日换手率达到20%的前5只股票 | | | | | | 买/卖 | 营业部或交易单元名称 | | | 买入金额（元） | 卖出金额（元） | | 买1 | 中信建投证券股份有限公司北京方庄路证券营业部 | | | 4920892.49 | 0 | | 买2 | 国元证券股份有限公司深圳百花二路营业部 | | | 4917400 | 47345.69 | | 买3 | 东莞证券股份有限公司四川分公司 | | | 3977038.12 | 1146764.47 | | 买4 | 申万宏源证券有限公司天津解放南路营业部 | | | 3917399.02 | 3850442.8 | | 买5 | 东方财富证券股份有限公司拉萨团结路第二证券营业部 | | | 3801118.03 | ...

| 日期 | 代码 | 简称 | 成交数量（股） | 成交金额（万元） | 披露原因 | | --- | --- | --- | --- | --- | --- | | 2024-10- | 834770 | 艾能聚 | 59087063.0 | 69405.05 | 异常期间涨跌幅偏离值累计 | | 24 | | | | | 达到60.44% | | 2024-10- | 873169 | 七丰精工 | 24713706.0 | 33423.61 | 异常期间涨跌幅偏离值累计 | | 24 | | | | | 达到60.43% | | 2024-10- | 831689 | 克莱特 | 25339180.0 | 45987.11 | 异常期间涨跌幅偏离值累计 | | 24 | | | | | 达到49.77% | | 2024-10- | 836149 | 旭杰科技 | 37397189.0 | 45007.98 | 异常期间涨跌幅偏离值累计 | | 24 | | | | | 达到45.56% | | 2024-10- | 871553 | 凯腾精工 | 33180523.0 | 24242.39 | 异常 ...

| | 公告日期 2024-10-24 | 异常期间 | 无 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | | 美邦科技(832471) 连续竞价 | 成交数量 | 5488776 | 成交金额（万 | 9261 | | | | | | （股） | | 元） | | | | | | 涉及事项 当日收盘价涨幅达到20%的前5只股票 | | | | | | | | 买/卖 | 营业部或交易单元名称 | | | 买入金额（元） | 卖出金额（元） | | | | 买1 | 东方财富证券股份有限公司拉萨东环路第二证券营业部 | | | 6502203.37 | | 373330.51 | | | 买2 | 甬兴证券有限公司宁波和源路证券营业部 | | | 6381852.18 | | | 0 | | 买3 | 华泰证券股份有限公司长沙韶山北路证券营业部 | | | 5203050 | | | 0 | | 买4 | 中信建投证券股份有限公司福州东街证券营业部 | | | 2720612.18 | | | 0 | | 买5 | 兴业证券股份有限 ...

Group 1 - Meibang Technology's stock price reached a historical high, increasing by 29.95% to 17.27 yuan, with a trading volume of 2.8852 million shares and a turnover of 47.6466 million yuan, resulting in a turnover rate of 10.09% [1] - The latest total market capitalization of Meibang Technology in A-shares is 1.437 billion yuan, with a circulating market value of 494 million yuan [1] - The basic chemical industry, to which Meibang Technology belongs, has an overall decline of 0.28%, with 119 stocks rising and 269 stocks falling [1] Group 2 - The latest margin trading data shows that as of October 23, the margin balance for Meibang Technology is 2.7747 million yuan, with a financing balance of 2.7747 million yuan, reflecting a recent increase of 519,500 yuan, or 23.04% [1] - The company's semi-annual report indicates that it achieved an operating income of 268 million yuan in the first half of the year, representing a year-on-year growth of 24.93%, and a net profit of 19.3259 million yuan, up 195.82% year-on-year [1] - The basic earnings per share for the company is 0.2339 yuan, with a weighted average return on equity of 3.40% [1]

Group 1: Investor Relations Activity Overview - The investor relations activity was held on October 15, 2024, via an online platform [2] - Participants included the company's chairman, general manager, vice president, and financial officer [2] Group 2: Key Questions and Responses - Question regarding the R&D and market development status of β-Nicotinamide Mononucleotide (NMN) products was addressed, confirming that the subsidiary has completed the enzyme process development and is optimizing parameters [3] - Inquiry about the core technologies of the subsidiary, including gene editing, synthetic biology, and enzyme engineering, was answered, highlighting the development of various products such as Nylon 56 and Glutathione (GSH) [4]